Dihydroartemisinin as a Sensitizing Agent in Cancer Therapies

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Guo Z. Development of artemisinin antimalarials. Acta Pharm Sin. 2016;51(1):157–164. doi:10.16438/j.0513-4870.2015-1036
   Google Scholar
• Li G, Zhou Q, Zhao C, Qu F, Huang L. Current research status of artemisinins. Clin Pharm J. 1998;33(7):3–5. doi:10.3321/j.issn:1001-2494
   Google Scholar
• Xu CC, Deng T, Fan MC, Lv WB, Liu JH, Yu BY. Synthesis and in vitro antitumor evaluation of dihydroartemisinin-cinnamic acid ester derivatives. Eur J Med Chem. 2016;107:192–203. doi:10.1016/j.ejmech.2015.11.003
   PubMed Web of Science ®Google Scholar
• Li BN, Bu SX, Sun JY, Guo Y, Lai DM. Artemisinin derivatives inhibit epithelial ovarian cancer cells via autophagy-mediated cell cycle arrest. Acta Biochim Biophys Sin. 2018;50(12):1227–1235. doi:10.1093/abbs/gmy125
   Google Scholar
• Xu CH, Liu Y, Xiao LM, et al. Dihydroartemisinin treatment exhibits antitumor effects in glioma cells through induction of apoptosis. Mol Med Rep. 2017;16(6):9528–9532. doi:10.3892/mmr.2017.7832
   PubMed Web of Science ®Google Scholar
• Dong FY, Zhou X, Li CS, et al. Dihydroartemisinin targets VEGFR2 via the NF-κB pathway in endothelial cells to inhibit angiogenesis. Cancer Biol Ther. 2014;15(11):1479–1488. doi:10.4161/15384047.2014.955728
   PubMed Web of Science ®Google Scholar
• Jiang J, Geng GJ, Yu XY, et al. Repurposing the anti-malarial drug dihydroartemisinin suppresses metastasis of non-small-cell lung cancer via inhibiting NF-κB/GLUT1 axis. Oncotarget. 2016;7(52):87271–87283. doi:10.18632/oncotarget.13536
   PubMedGoogle Scholar
• Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res. 2000;6(7):2585–2597.
   Google Scholar
• Chen X, Lai M, Tang P, Lai H. Study the influence mechanism of luteolin combined with temozolomide on glioma. Pharm Clin Chin Materia Medica. 2017;33(2):63–66.
   Google Scholar
• Choi EJ, Cho BJ, Lee DJ, et al. Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases. BMC Cancer. 2014;14:17. doi:10.1186/1471-2407-14-17
   PubMed Web of Science ®Google Scholar
• Zhang WB, Wang Z, Shu F, et al. Activation of AMP-activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition. J Biol Chem. 2010;285(52):40461–40471. doi:10.1074/jbc.M110.164046
   PubMed Web of Science ®Google Scholar
• Jiapaer S, Furuta T, Tanaka S, Kitabayashi T, Nakada M. Potential strategies overcoming the temozolomide resistance for glioblastoma. Neurol Med Chir. 2018;58(10):405–421. doi:10.2176/nmc.ra.2018-0141
   PubMed Web of Science ®Google Scholar
• Yan J, Wen J, Chen H, Huang Q, Li X, Mo L. The research on dihydroartemisinin combined with temozolomide inhibits the proliferation and induces apoptosis of glioma cells. Chin J Exp Surg. 2019;36(2):274–276. doi:10.3760/cma.j.issn.1001-9030.2019.02.025
   Google Scholar
• Zhang ZS, Wang J, Shen YB, et al. Dihydroartemisinin increases temozolomide efficacy in glioma cells by inducing autophagy. Oncol Lett. 2015;10(1):379–383. doi:10.3892/ol.2015.3183
   PubMed Web of Science ®Google Scholar
• Huang XJ, Li CT, Zhang WP, Lu YB, Fang SH, Wei EQ. Dihydroartemisinin potentiates the cytotoxic effect of temozolomide in rat C6 glioma cells. Pharmacology. 2008;82(1):1–9. doi:10.1159/000125673
   PubMed Web of Science ®Google Scholar
• Lemke D, Pledl HW, Zorn M, et al. Slowing down glioblastoma progression in mice by running or the anti-malarial drug dihydroartemisinin? Induction of oxidative stress in murine glioblastoma therapy. Oncotarget. 2016;7(35):56713–56725. doi:10.18632/oncotarget.10723
   PubMedGoogle Scholar
• Nussbaumer S, Bonnabry P, Veuthey JL, Fleury-Souverain S. Analysis of anticancer drugs: a review. Talanta. 2011;85(5):2265–2289. doi:10.1016/j.talanta.2011.08.034
   Google Scholar
• Liu C, Liu G. Progress in gemcitabine resistance mechanism of pancreatic cancer cells. People’s Military Surgeon. 2019;62(12):1211–1216.
   Google Scholar
• Nakano T, Saiki Y, Kudo C, et al. Acquisition of chemoresistance to gemcitabine is induced by a loss-of-function missense mutation of DCK. Biochem Biophys Res Commun. 2015;464(4):1084–1089. doi:10.1016/j.bbrc.2015.07.080
   PubMed Web of Science ®Google Scholar
• Yang SC, Zhang DW, Shen N, Wang GY, Tang ZH, Chen XS. Dihydroartemisinin increases gemcitabine therapeutic efficacy in ovarian cancer by inducing reactive oxygen species. J Cell Biochem. 2019;120(1):634–644. doi:10.1002/jcb.27421
   PubMed Web of Science ®Google Scholar
• Zhao CB, Gao WJ, Chen TS. Synergistic induction of apoptosis in A549 cells by dihydroartemisinin and gemcitabine. Apoptosis. 2014;19(4):668–681. doi:10.1007/s10495-013-0953-0
   PubMed Web of Science ®Google Scholar
• Zhao CB, Qin GQ, Gao WJ, et al. Potent proapoptotic actions of dihydroartemisinin in gemcitabine-resistant A549 cells. Cell Signal. 2014;26(10):2223–2233. doi:10.1016/j.cellsig.2014.07.001
   PubMed Web of Science ®Google Scholar
• Wang SJ, Gao Y, Chen H, et al. Dihydroartemisinin inactivates NF-kappaB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo. Cancer Lett. 2010;293(1):99–108. doi:10.1016/j.canlet.2010.01.001
   PubMed Web of Science ®Google Scholar
• Wang S, Sun B, Pan S, et al. Experimental study of the function and mechanism combining dihydroartemisinin and gemcitabine in treating pancreatic cancer. Chin J Surg. 2010;48(7):530–534. doi:10.3760/cma.j.issn.0529-5815.2010.07.013
   PubMedGoogle Scholar
• Shao Z, Xiang S, Zhu J, Zou J. Experimental study of dihydroartemisinin combined with gemcitabine in the treatment of cholangiocarcinoma. Shenzhen J Integr Tradit Chin West Med. 2016;26(22):4–6. doi:10.16458/j.cnki.1007-0893.2016.22.002
   Google Scholar
• Baba H, Teramoto K, Kawamura T, Mori A, Imamura M, Arii S. Dihydropyrimidine dehydrogenase and thymidylate synthase activities in hepatocellular carcinomas and in diseased livers. Cancer Chemother Pharmacol. 2003;52(6):469–476. doi:10.1007/s00280-003-0695-8
   PubMed Web of Science ®Google Scholar
• Dai ZR, Mao QF. Dihydroartemisinin increases sensitivity of gastric cancer cells to 5 -fluorouracil through suppression of ATF2 phosphorylation. Zhejiang JITCW M. 2018;28(5):363–365, 369.
   Google Scholar
• Wan B, Cao HB, Yu GH. Dihydroartemisinin enhances antitumor effect of 5-fluorouracil against gastric cancer by down-regulating SIRT1 expression. Chin J Pathophysiol. 2017;33(12):2195–2201.
   Google Scholar
• Yao ZH, Bhandari A, Wang YH, et al. Dihydroartemisinin potentiates antitumor activity of 5-fluorouracil against a resistant colorectal cancer cell line. Biochem Biophys Res Commun. 2018;501(3):636–642. doi:10.1016/j.bbrc.2018.05.026
   PubMed Web of Science ®Google Scholar
• Yang Y, He JX, Chen J, et al. Dihydroartemisinin sensitizes mutant p53 (r248q)-expressing hepatocellular carcinoma cells to doxorubicin by inhibiting p-gp expression. Biomed Res Int. 2019;2019:8207056. doi:10.1155/2019/8207056
   PubMed Web of Science ®Google Scholar
• Kang XJ, Wang HY, Peng HG, et al. Codelivery of dihydroartemisinin and doxorubicin in mannosylated liposomes for drug-resistant colon cancer therapy. Acta Pharmacol Sin. 2017;38(6):885–896. doi:10.1038/aps.2017.10
   PubMed Web of Science ®Google Scholar
• Hu YJ, Zhang JY, Luo Q, et al. Nanostructured dihydroartemisinin plus epirubicin liposomes enhance treatment efficacy of breast cancer by inducing autophagy and apoptosis. Nanomaterials. 2018;8(10):804. doi:10.3390/nano8100804
   Web of Science ®Google Scholar
• Tai X, Cai XB, Zhang Z, Wei R. In vitro inhibition of tumor cell viability by combined dihydroartemisinin and doxorubicin treatment, and the underlying mechanism. Oncol Lett. 2016;12(5):3701–3706. doi:10.3892/ol.2016.5187
   PubMed Web of Science ®Google Scholar
• Liu JJ, Tang W, Fu M, et al. Development of R8 modified epirubicin–dihydroartemisinin liposomes for treatment of non-small-cell lung cancer. Artif Cells Nanomed Biotechnol. 2019;47(1):1947–1960. doi:10.1080/21691401.2019.1615932
   PubMed Web of Science ®Google Scholar
• Wong PM, Feng Y, Wang JR, Shi R, Jiang XJ. Regulation of autophagy by coordinated action of mTORC1 and protein phosphatase 2A. Nat Commun. 2015;6:8048. doi:10.1038/ncomms9048
   PubMed Web of Science ®Google Scholar
• Wang LM, Wang RL. Effect of rapamycin (RAPA) on the growth of lung cancer and its mechanism in mice with A549. Int J Clin Exp Pathol. 2015;8(8):9208–9213.
   PubMed Web of Science ®Google Scholar
• Chen K, Lv S. Resistant mechanism about rapamycin and solution. J Int Oncol. 2014;41(10):740–743. doi:10.3760/cma.j.issn.1673-422X.2014.10.007
   Google Scholar
• Zhong X, Wang A, Wang H, Feng J, Zheng B, Shi H. DHA-inhibited proliferation through the PTEN/PI3K/Akt pathway in gastric cancer SGC7901 cells. Chin J Clin Oncol. 2013;4:190–194. doi:10.3969/j.issn.1000-8179.2013.04.003
   Google Scholar
• Thongchot S, Vidoni C, Ferraresi A, et al. Dihydroartemisinin induces apoptosis and autophagy-dependent cell death in cholangiocarcinoma through a DAPK1-BECLIN1 pathway. Mol Carcinog. 2018;57(12):1735–1750. doi:10.1002/mc.22893
   PubMed Web of Science ®Google Scholar
• Liu QJ, Zhou XY, Li C, Zhang XM, Li CL. Rapamycin promotes the anticancer action of dihydroartemisinin in breast cancer MDA-MB-231 cells by regulating expression of Atg7 and DAPK. Oncol Lett. 2018;15(4):5781–5786. doi:10.3892/ol.2018.8013
   PubMed Web of Science ®Google Scholar
• Chen LP, Wang L, Shen HB, Lin H, Li D. Anthelminthic drug niclosamide sensitizes the responsiveness of cervical cancer cells to paclitaxel via oxidative stress-mediated mTOR inhibition. Biochem Biophys Res Commun. 2017;484(2):416–421. doi:10.1016/j.bbrc.2017.01.140
   PubMed Web of Science ®Google Scholar
• Huang D, Li L, Na X. Inhibitory effect of dihydroartemisinin combined with paclitaxel on proliferation of breast cancer cells. J Front Med. 2018;8(14):160. doi:10.3969/j.issn.2095-1752.2018.14.125
   Google Scholar
• Paccez J, Duncan K, Sekar D, et al. Dihydroartemisinin inhibits prostate cancer via JARID2/miR-7/miR-34a-dependent downregulation of Axl. Oncogenesis. 2019;8(3):14. doi:10.1038/s41389-019-0122-6
   PubMedGoogle Scholar
• Dai Phung C, Le TG, Nguyen VH, et al. PEGylated-paclitaxel and dihydroartemisinin nanoparticles for simultaneously delivering paclitaxel and dihydroartemisinin to colorectal cancer. Pharm Res. 2020;37(7):129. doi:10.1007/s11095-020-02819-7
   PubMed Web of Science ®Google Scholar
• Guan F, Ding YM, Zhang YM, Zhou Y, Li MG, Wang CH. Curcumin suppresses proliferation and migration of MDA-MB-231 breast cancer cells through autophagy-dependent Akt degradation. PLoS One. 2016;11(1):e0146553. doi:10.1371/journal.pone.0146553
   PubMed Web of Science ®Google Scholar
• Khan MA, Zafaryab M, Mehdi SH, Ahmad I, Rizvi MM. Characterization and anti-proliferative activity of curcumin loaded chitosan nanoparticles in cervical cancer. Int J Biol Macromol. 2016;93(Pt.A):242–253. doi:10.1016/j.ijbiomac.2016.08.050
   PubMedGoogle Scholar
• Gabriel S, Felipe TL, Viviane S, et al. Curcumin analog CH-5 suppresses the proliferation, migration, and invasion of the human gastric cancer cell line HGC-27. Molecules. 2018;23(2):279. doi:10.3390/molecules23020279
   PubMed Web of Science ®Google Scholar
• Gaikwad D, Shewale R, Patil V, Mali D, Gaikwad U, Jadhav N. Enhancement in in vitro anti-angiogenesis activity and cytotoxicity in lung cancer cell by pectin-PVP based curcumin particulates. Int J Biol Macromol. 2017;104(Pt.A):656–664. doi:10.1016/j.ijbiomac.2017.05.170
   PubMedGoogle Scholar
• Starok M, Preira P, Vayssade M, Haupt K, Salomé L, Rossi C. EGFR inhibition by curcumin in cancer cells: a dual mode of action. Biomacromolecules. 2015;16(5):1634–1642. doi:10.1021/acs.biomac.5b00229
   PubMed Web of Science ®Google Scholar
• Zhao JJ, Pan YC, Li XJ, et al. Dihydroartemisinin and curcumin synergistically induce apoptosis in SKOV3 cells via upregulation of MiR-124 targeting midkine. Cell Physiol Biochem. 2017;43(2):589–601. doi:10.1159/000480531
   PubMedGoogle Scholar
• Ohmichi M, Hayakawa J, Tasaka K, Kurachi H, Murata Y. Mechanisms of platinum drug resistance. Trends Pharmacol Sci. 2005;26(3):113–116. doi:10.1016/j.tips.2005.01.002
   PubMed Web of Science ®Google Scholar
• Delbridge AR, Grabow S, Strasser A, Vaux DL. Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies. Nat Rev Cancer. 2016;16(2):99–109. doi:10.1038/nrc.2015.17
   PubMed Web of Science ®Google Scholar
• Zhang SY, Feng R, Yuan F, et al. The therapeutic effects of dihydroartemisinin on cisplatin-resistant gastric cancer cells. Curr Pharm Biotechnol. 2021;22. doi:10.2174/1389201022666210217114825
   Google Scholar
• Feng X, Li L, Jiang H, Jiang KP, Jin Y, Zheng JH. Dihydroartemisinin potentiates the anticancer effect of cisplatin via mTOR inhibition in cisplatin-resistant ovarian cancer cells: involvement of apoptosis and autophagy. Biochem Biophys Res Commun. 2014;444(3):376–381. doi:10.1016/j.bbrc.2014.01.053
   PubMed Web of Science ®Google Scholar
• Cui W, Fang TT, Duan ZH, et al. Dihydroartemisinin sensitizes esophageal squamous cell carcinoma to cisplatin by inhibiting sonic hedgehog signaling. Front Cell Dev Biol. 2020;8:596788. doi:10.3389/fcell.2020.596788
   PubMed Web of Science ®Google Scholar
• Qin Y, Yang G, Li M, et al. Dihydroartemisinin inhibits EMT induced by platinum-based drugs via Akt-Snail pathway. Oncotarget. 2017;8(61):103815–103827. doi:10.18632/oncotarget.21793
   PubMedGoogle Scholar
• Zhang BC, Zhang ZM, Wang J, et al. Dihydroartemisinin sensitizes Lewis lung carcinoma cells to carboplatin therapy via p38 mitogen-activated protein kinase activation. Oncol Lett. 2018;15(5):7531–7536. doi:10.3892/ol.2018.8276
   PubMed Web of Science ®Google Scholar
• Feng M, Ding J, Liu S, Tian J, Sun BWL, Guan WX. The effect of gender on endoplasmic reticulum-stress (ER-stress) and apoptosis signals in patients with hepatocellular carcinoma. J Jiangsu Univ. 2017;27(05):432–436.
   Google Scholar
• Ezzoukhry Z, Louandre C, Trécherel E, et al. EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib. Int J Cancer. 2012;131(12):2961–2969. doi:10.1002/ijc.27604
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhou XY, Shen HJ, Wang DX, Wang YH. Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study. BMC Med. 2009;7:41. doi:10.1186/1741-7015-7-41
   PubMed Web of Science ®Google Scholar
• Shimizu S, Takehara T, Hikita H, et al. Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma. Int J Cancer. 2012;131(3):548–557. doi:10.1002/ijc.26374
   PubMed Web of Science ®Google Scholar
• Hou CY, Guo DQ, Yu X, Wang SY, Liu TH. TMT-based proteomics analysis of the anti-hepatocellular carcinoma effect of combined dihydroartemisinin and sorafenib. Biomed Pharmacother. 2020;126:109862. doi:10.1016/j.biopha.2020.109862
   Google Scholar
• Wang ZF, Duan XX, Lv YH, Zhao YF. Low density lipoprotein receptor (LDLR)-targeted lipid nanoparticles for the delivery of sorafenib and Dihydroartemisinin in liver cancers. Life Sci. 2019;239:117013. doi:10.1016/j.lfs.2019.117013
   Google Scholar
• Kiyota M, Kuroda J, Yamamoto-Sugitani M, et al. FTY720 induces apoptosis of chronic myelogenous leukemia cells via dual activation of BIM and BID and overcomes various types of resistance to tyrosine kinase inhibitors. Apoptosis. 2013;18(11):1437–1446. doi:10.1007/s10495-013-0882-y
   PubMed Web of Science ®Google Scholar
• Ng KP, Hillmer AM, Chuah CT, et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med. 2012;18(4):521–528. doi:10.1038/nm.2713
   PubMed Web of Science ®Google Scholar
• Deng QF, Fang QY, Ji XX, Zhou SW. Cyclooxygenase-2 mediates gefitinib resistance in non-small cell lung cancer through the EGFR/PI3K/AKT axis. J Cancer. 2020;11(12):3667–3674. doi:10.7150/jca.42850
   PubMed Web of Science ®Google Scholar
• Jin H, Jiang AY, Wang H, Cao Y, Wu Y, Jiang XF. Dihydroartemisinin and gefitinib synergistically inhibit NSCLC cell growth and promote apoptosis via the Akt/mTOR/STAT3 pathway. Mol Med Rep. 2017;16(3):3475–3481. doi:10.3892/mmr.2017.6989
   PubMed Web of Science ®Google Scholar
• Song F, Luo M, Fan N, Zhou J, Li Y. Combination of dihydroartemisinin and gefitinib inhibits cell cycle and migration of lung adenocarcinoma cells in vitro. Armed Police Med. 2019;30(03):228–232.
   Google Scholar
• Bellini L, Strub T, Habel N, et al. Endoplasmic reticulum stress mediates resistance to BCL-2 inhibitor in uveal melanoma cells. Cell Death Discov. 2020;6:22. doi:10.1038/s41420-020-0259-2
   PubMed Web of Science ®Google Scholar
• Inoue-Yamauchi A, Oda H. EMT-inducing transcription factor ZEB1-associated resistance to the BCL-2/BCL-X L inhibitor is overcome by BIM upregulation in ovarian clear cell carcinoma cells. Biochem Biophys Res Commun. 2020;526(3):612–617. doi:10.1016/j.bbrc.2020.03.139
   PubMed Web of Science ®Google Scholar
• Yan XH, Li PF, Zhan YH, et al. Dihydroartemisinin suppresses STAT3 signaling and Mcl-1 and Survivin expression to potentiate ABT-263-induced apoptosis in non-small cell lung cancer cells harboring EGFR or RAS mutation. Biochem Pharmacol. 2018;150:72–85. doi:10.1016/j.bcp.2018.01.031
   PubMed Web of Science ®Google Scholar
• Budhraja A, Turnis ME, Churchman ML, et al. Modulation of navitoclax sensitivity by dihydroartemisinin-mediated MCL-1 repression in BCR-ABL+ B-lineage acute lymphoblastic leukemia. Clin Cancer Res. 2017;23(24):7558–7568. doi:10.1158/1078-0432.CCR-17-1231
   PubMed Web of Science ®Google Scholar
• Kempf H, Hatzikirou H, Bleicher M, Meyer-Hermann M. In silico analysis of cell cycle synchronisation effects in radiotherapy of tumour spheroids. PLoS Comput Biol. 2013;9(11):e1003295. doi:10.1371/journal.pcbi.1003295.
   Google Scholar
• Zuo Z, Wang J, Wang S, Xin Y, Zhang H. The sensitizing effects of combined treatment with dihydroartemisinin and irradiation on human lung cancer in nude mice. J Modern Oncol. 2013;21(12):2687–2691. doi:10.3969/j.issn.1672-4992.2013.12.13
   Google Scholar
• Zuo Z, Wang S, Jiang L, Xin Y, Li W. Effect of dihydroartemisinin combined irradiation on the apoptosis of human lung cancer GLC-82 cells and its mechanism study. Chin J Integr Tradt Chin West Med. 2014;34(10):1220–1224.
   Google Scholar
• Zhang H, Zhou F, Wang YY, et al. Eliminating radiation resistance of non-small cell lung cancer by dihydroartemisinin through abrogating immunity escaping and promoting radiation sensitivity by inhibiting PD-L1 expression. Front Oncol. 2020;10:595466. doi:10.3389/fonc.2020.595466
   PubMed Web of Science ®Google Scholar